EUVIMEDEUVIMED entdecken
Crossref

Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study

Yusuke Miyazaki iD, Satoshi Kubo iD, Shunsuke Fukuyo, Ippei Miyagawa iD, Ayako Yamaguchi, Yurie Satoh-Kanda, Yasuyuki Todoroki, Hiroaki Tanaka, Masanobu Ueno, Ryuichiro Kanda iD, Yuya Fujita iD, Hidenori Sakai und 2 weitere

Modern Rheumatology · 17.10.2026

DOI: 10.1093/mr/roag089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 17.10.2026. Verfasst von Yusuke Miyazaki und 13 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, University of Occupational and Environmental Health, Japan. Die Arbeit nennt 22 Literaturangaben. Gefördert von: University of Occupational & Environmental Health, Japan (UOEH) for Advanced Research, University of Occupational and Environmental Health, Japan, Grant-In-Aid for Scientific Research from the University of Occupational and Environmental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to evaluate treatment persistence and safety following subcutaneous methotrexate (MTX) initiation in Japanese patients with rheumatoid arthritis and clinical outcomes after direct switching from oral to subcutaneous MTX.

Methods

We retrospectively studied 101 patients with rheumatoid arthritis initiating subcutaneous MTX. Efficacy and safety were analysed in patients switching because of adverse events. The primary endpoint was the 26-week retention rate.

Results

Gastrointestinal intolerance was the commonest reason for switching from oral to subcutaneous MTX. Overall retention rate was 87.1% (88/101). Among switchers, the 26-week retention rate was 92.0% (81/88), and the MTX dose increased in 46.6% (41/88). In patients not receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs at switching (n = 50), the retention rate was 96.0% (48/50), and the mean MTX dose increased (10.3 ± 2.8 to 12.0 ± 2.8 mg/week; P < .0001). The Clinical Disease Activity Index improved by week 26 (13.2 ± 10.1 to 8.2 ± 7.8; P < .0001), with 30.0% (15/50) achieving remission.

Conclusions

Switching from oral to subcutaneous MTX in patients with rheumatoid arthritis who are intolerant to oral MTX may enable continued treatment and dose optimization and be associated with improved disease activity.

Schlagwörter

Stichwörter der Autor:innen

dose escalationgastrointestinal intolerancemethotrexaterheumatoid arthritissubcutaneous methotrexate

Autor:innen und Institutionen

  • First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
  • Department of molecular targeted therapeutics, University of Occupational and Environmental Health, Japan.
  • Department of Laboratory and Transfusion Medicine, Hospital of the University of Occupational and Environmental Health, Japan.

ORCID-Profile: Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Ryuichiro Kanda, Yuya Fujita, Shingo Nakayamada, Yoshiya Tanaka

Förderung

  • University of Occupational & Environmental Health, Japan (UOEH) for Advanced Research
  • University of Occupational and Environmental Health, Japan
  • Grant-In-Aid for Scientific Research from the University of Occupational and Environmental Health
  • University of Occupational & Environmental Health

Zitieren

APA

Miyazaki, Y., Kubo, S., Fukuyo, S., Miyagawa, I., Yamaguchi, A., Satoh-Kanda, Y., Todoroki, Y., Tanaka, H., Ueno, M., Kanda, R., Fujita, Y., Sakai, H., Nakayamada, S., & Tanaka, Y. (2026). Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study. Modern Rheumatology. https://doi.org/10.1093/mr/roag089

Vancouver

Miyazaki Y, Kubo S, Fukuyo S, Miyagawa I, Yamaguchi A, Satoh-Kanda Y, et al. Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study. Modern Rheumatology. 2026. doi:10.1093/mr/roag089

BibTeX
@article{Miyazaki2026,
  author = {Miyazaki, Yusuke and Kubo, Satoshi and Fukuyo, Shunsuke and Miyagawa, Ippei and Yamaguchi, Ayako and Satoh-Kanda, Yurie and Todoroki, Yasuyuki and Tanaka, Hiroaki and Ueno, Masanobu and Kanda, Ryuichiro and Fujita, Yuya and Sakai, Hidenori and Nakayamada, Shingo and Tanaka, Yoshiya},
  title = {Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study},
  journal = {Modern Rheumatology},
  year = {2026},
  doi = {10.1093/mr/roag089}
}
Kostenlos starten →